Appili Therapeutics Inc. (T:APLI)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEDAR | |
| Company Contact | |
| Address: | #21-1344 Summer Street HALIFAX NS B3H 0A8 |
| Tel: | N/A |
| Website: | www.appilitherapeutics.com |
| IR: | See website |
| Key People | ||
| Ian C. Mortimer Independent Chairman of the Board | Armand Balboni Chief Executive Officer, Director | Kimberly Stephens Chief Financial Officer, Corporate Secretary |
| Myriam Triest Senior Director - Product Development | Don Cilla Chief Development Officer | Yoav Golan Chief Medical Officer |
| Business Overview |
| Appili Therapeutics Inc is a Canada-based pharmaceutical company. The Company is focused on the acquisition and development of treatments targeting infectious disease. The Company is focused on building and advancing adverse portfolio of anti-infective programs. The Company's anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is a clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections. The ATI-1701 is a vaccine candidate for tularemia. The ATI-1503 is a drug discovery program aimed at generating a class of antibiotics with broad spectrum activity against gram-negative superbugs. The ATI-1501 employs its taste-masked, oral-suspension technology with metronidazole for the patients with difficulty swallowing. |
| Financial Overview |
| For the six months ended 30 September 2020, AppiliTherapeutics Inc revenues was not reported. Net lossincreased 72% to C$5.1M. Higher net loss reflects Researchand development - Remaining increase from C$609K to C$2.1M(expense), General and administrative - Balancing increaseof 38% to C$1.4M (expense), Stock-based compensation in G&Aexpenses increase from C$176K to C$510K (expense). |
| Employees: | 11 as of Mar 31, 2019 |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $61.18M as of Sep 30, 2020 |
| Annual revenue (TTM): | $0.20M as of Sep 30, 2020 |
| EBITDA (TTM): | -$8.21M as of Sep 30, 2020 |
| Net annual income (TTM): | -$7.54M as of Sep 30, 2020 |
| Free cash flow (TTM): | -$5.94M as of Sep 30, 2020 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 62,575,368 as of Jan 11, 2021 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Company fundamental and
price data sourced from © Thomson Reuters Limited. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent
of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for
any actions taken in reliance on such content. 'Thomson Reuters' and the Thomson Reuters logo are trademarks of
Thomson Reuters and its affiliated companies. US Quotes data provided by IEX.
Interactive technical study charts by TradingView. Copyright © 2021 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.